Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 9, 2008 - Issue 2
Submit an article Journal homepage
1,029
Views
75
CrossRef citations to date
0
Altmetric
Drug Evaluations

Oral valproic acid for epilepsy - long-term experience in therapy and side effects

Thorsten Gerstner University Children's Hospital, Neuropediatric Unit, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany +49 621 3832466; +49 621 3833828; [email protected]
,
Nellie Bell University Children's Hospital, Neuropediatric Unit, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany +49 621 3832466; +49 621 3833828; [email protected]
&
Stephan König University Children's Hospital, Neuropediatric Unit, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany +49 621 3832466; +49 621 3833828; [email protected]
Pages 285-292 | Published online: 17 Jan 2008

Bibliography

  • Aldenkamp A, Vigevano F, Arzimanoglou A, Covanis A. Role of valproate across the ages. Treatment of epilepsy in children. Acta Neurol Scand 2006;184(Suppl):1-13
  • Davis R, Peters DH, McTavish D. Valproic acid. A reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1994;47:332-72
  • Silberstein SD. Divalproex sodium in headache: literature review and clinical guidelines. Headache 1996;36:547-55
  • Cutrer FM, Moskowitz MA. Wolff Award 1996. The actions of valproate and neurosteroids in a model of trigeminal pain. Headache 1996;36:579-85
  • Bowden CL, Brugger AM, Swann AC, et al. Efficacy of divalproex vs. lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA 1994;271:918-24
  • Chavez-Blanco A, Perez-Plasencia C, Perez-Cardenas E, et al. Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines. Cancer Cell Int 2006;6:2
  • Brichta L, Hofmann Y, Hahnen E, et al. Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum Mol Genet 2003;12:2481-9
  • Rouaux C, Panteleeva I, René F, et al. Sodium valproate exerts neuroprotective effects in vivo through CREB-binding protein-dependent mechanisms but does not improve survival in an amyotrophic lateral sclerosis mouse model. J Neurosci 2007;23(27):5535-45
  • Walia KS, Khan EA, Ko DH, et al. Side effects of antiepileptics – a review. Pain Pract 2004;4:194-203
  • Hirsch E, Genton P. Antiepileptic drug-induced pharmacodynamic aggravation of seizures. CNS Drugs 2003;17:633-40
  • McLachlan RS. Pseudoatrophy of the brain with valproic acid monotherapy. Can J Neurol Sci 1987;14(3):294-96
  • Guerrini R, Belmonte A, Canapicchi R et al. Reversible pseudoatrophy of the brain and mental deterioration associated with valproate treatment. Epilepsia 1998;39(1):27-32
  • Koenig SA, Schenk M, Sick C, et al. Fatal liver failure associated with valproate therapy in a patient with Friedreich's disease: review of valproate hepatotoxicity in adults. Epilepsia 1999;40:1036-40
  • Gerstner T, Bauer MO, Longin E, et al. Reversible hepatotoxicity, pancreatitis, coagulation disorder and simultaneous bone marrow suppression with valproate in a 2-year-old girl. Seizure 2007;16:554-6
  • Gerstner T, Teich M, Bell N, et al. Valproate-associated coagulopathies are frequent and variable in children. Epilepsia 2006;47:1136-43
  • Nau H. Valproic acid-induced neural tube defects. Ciba Found Symp 1994;181:144-52
  • DeVane CL. Pharmacokinetics, drug interactions, and tolerability of valproate. Psychopharmacol Bull 2003;37:25-42
  • Dodge JC, Illig AM, Snyder PJ, Badura LL. GABA levels within the medial preoptic area: effects of chronic administration of sodium valproic acid. Psychoneuroendocrinology 2000;25:519-34
  • Makarska-Bialek K, Kaminski RM, Czuczwar SJ. Influence of the antagonist of the glycine site of NMDA receptors, MRZ 2/576, on the anticonvulsant activity of conventional antiepileptic drugs in mice. Pharmacol Rep 2005;57:458-66
  • Pugsley MK, Yu EJ, Mclean TH, Goldin AL. Blockade of neuronal sodium channels by the antiepileptic drugs phenytoin, carbamazepine and sodium valproate. Proc West Pharmacol Soc 1999;42:105-8
  • Clemens B. Valproate decreases EEG synchronization in a use-dependent manner in idiopathic generalized epilepsy. Seizure; Epub 2007
  • Béla C, Mónika B, Márton T, István K. Valproate selectively reduces EEG activity in anterior parts of the cortex in patients with idiopathic generalized epilepsy. A low resolution electromagnetic tomography (LORETA) study. Epilepsy Res 2007;75:186-91
  • McDonald RL, McLean MJ. Anticonvulsant drugs: mechanisms of action. In: Advances in Neurology, Volume 44. Basic Mechanisms of the Epilepsies. Delgado-Esscueta AV, editor. Raven, New York, p. 713-36
  • Koenig St, Knolle J, Friedewald St, et al. The effects of valproic acid, carbamazepine and phenobarbitone on the fatty acid composition of erythrocyte membranes in children. Epilepsia 2003;44:708-11
  • Rosenberg G. The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees? Cell Mol Life Sci 2007;64:2090-103
  • Tang Y, Glauser TA, Gilbert DL, et al. Valproic acid blood genomic expression patterns in children with epilepsy - a pilot study. Acta Neurol Scand 2004;109:159-68
  • Perucca E, Gatti G, Frigo GM, et al. Disposition of sodium valproate in epileptic patients. Br J Clin Pharmacol 1978;5:495-9
  • Gugler R, von Unruh GE. Clinical pharmacokinetics of valproic acid. Clin Pharmacokinet 1980;5:67-83
  • Kreher U, Darius J, Wien F. Abnormal alterations in the metabolic patterns of patients on valproate therapy. J Pharm Pharmacol 2002;54:989-95
  • Klotz U. Bioavailability of a slow-release preparation of valproic acid under steady-state conditions. Int J Clin Pharmacol Ther Toxicol 1982;20:24-6
  • Brouwer OF, Pieters MS, Edelbroek PM, et al. Conventional and controlled release valproate in children with epilepsy: a cross-over study comparing plasma levels and cognitive performances. Epilepsy Res 1992;13:245-53
  • Loescher W, Honack D. Comparison of anticonvulsant efficacy of valproate during prolonged treatment with one and three daily doses or continuous (“controlled release”) administration in a model of generalized seizures in rats. Epilepsia 1995;36:929-37
  • Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 2002;16:695-714
  • Lee K, Melchior JC. Sodium valproate versus phenobarbital in the prophylactic treatment of febrile convulsions in childhood. Eur J Pediatr 1981;137:151-3
  • Ceulemans B, Boel M, Claes L, et al. Severe myoclonic epilepsy in infancy: toward an optimal treatment. J Child Neurol 2004;19:516-21
  • Tsuji T, Okumura A, Ozawa H, et al. Current treatment of West syndrome in Japan. J Child Neurol 2007;2:60-4
  • Selvitelli M, Drislane FW. Recent developments in the diagnosis and treatment of status epilepticus. Curr Neurol Neurosci Rep 2007;7:529-35
  • Agarwal P, Kumar N, Chandra R, et al. Randomized study of intravenous valproate and phenytoin in status epilepticus. Seizure 2007;16:527-32
  • Guerrini R. Valproate as a mainstay of therapy for pediatric epilepsy. Paediatr Drugs 2006;8:113-29
  • Gogtay NJ, Bavdekar SB, Kshirsagar NA. Anticonvulsant hypersensitivity syndrome: a review. Expert Opin Drug Saf 2005;4:571-81
  • Hurst DL. Expanded therapeutic range of valproate. Pediatr Neurol 1987;3:342-4
  • Boggs JP, Preis K. Successful initiation of combined therapy with valproate sodium injection and divalproex sodium extended-release tablets in the epilepsy monitoring unit. Epilepsia 2005;46:949-51
  • Dutta S, Cloyd JC, Granneman GR, Collins SD. Oral/intravenous maintenance dosing of valproate following intravenous loading: a simulation. Epilepsy Res 2003;53:29-38
  • Swadron SP, Rudis MI, Azimian K, et al. A comparison of phenytoin-loading techniques in the emergency department. Acad Emerg Med 2004;11:244-52
  • Gerstner T, Bell N, Longin E, Koenig S. Oral rapid loading of Valproic acid - an alternative to the usual saturation scheme? Seizure 2006;15:630-2
  • Pylvänen V, Pakarinen A, Knip M, Isojärdi J. Insulin-related metabolic changes during treatment with valproate in patients with epilepsy. Epilepsy Behav 2006;8:643-8
  • Egger J, Brett EM. Effects of sodium valproate in 100 children with special reference to weight. BMJ (Clin Res Ed) 1981;29(283):577-81
  • Khan TA, Sheng H, Mercke YK, Lippmann SB. Divalproex-induced alopecia: a case report. Psychiatr Serv 1999;50:1500
  • Schulpis KH, Karikas GA, Tjamouranis J, et al. Low serum biotinidase activity in children with valproic acid monotherapy. Epilepsia 2001;42:1359-62
  • Isojärdi JIT, Laatikainen TJ, Pakarinen AJ, et al. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993;329:1383-8
  • Nelson-De Grave VL, Wickenheisser JK, Cockrell JE, et al. Valproate potentiates androgen biosyntheses in human ovarian theca cells. Endocrinology 2004;145:799-808
  • Tauboll E, Gregoaszczuk EL, Kolodziej A, et al. Valproate inhibits the conversion of testosterone to estradiol and acts as an apoptotic agent in growing porcine ovarian follicular cells. Epilepsia 2003;44(8):1014-21
  • Herzog AG, Seibel MM, Schomer DL, et al. Reproductive endocrine disorders in women with partial seizures of temporal lobe origin. Arch Neurol 1986;43:341-6
  • Isojärvi JI. Reproductive dysfunction in women with epilepsy. Neurology 2003;61:27-34
  • Kim JY, Lee HW. Metabolic and hormonal disturbances in women with epilepsy on antiepileptic drug monotherapy. Epilepsia 2007;48:1366-70
  • Batalden PB, Van Dyne BJ, Cloyd J. Pancreatitis associated with valproic acid therapy. Pediatrics 1979;64:520-2
  • Camfield PR, Bagnell P, Camfield CS. Pancreatitis due to valproate acid. Lancet 1979;1:1198-9
  • Houben ML, Wilting I, Stroink H, van Dijken PJ. Pancreatitis, complicated by a pancreatic pseudocyst associated with the use of valproic acid. Eur J Paediatr Neurol 2005;9:77-80
  • Ascanapé JJ, Kiffin P, Dreifuss FE, et al. Valproate-associated pancreatitis. Epilepsia 1993;34:177-83
  • Pippenger CE, Xianzhong M, Rothner AD. Free radical scavenging enzyme activity profiles in risk assessment of idiosyncratic drug reactions: probable mechanism of valproate induced pancreatitis and hepatotoxicity. In: Idiosyncratic Reactions to Valproate: Clinical Risk Patterns and Mechanism of Toxicity. Levy RH, Penry JK, editors. New York, Raven Press; 1991. p. 75-88
  • Norgaard M, Jacobsen J, Ratanajamit C, et al. Valproic acid and risk of acute pancreatitis: a population-based case-control study. Am J Ther 2006;13:113-7
  • Gerstner T, Busing D, Bell N, et al. Valproic acid-induced pancreatitis: 16 new cases and a review of the literature. J Gastroenterol 2007;42:39-48
  • Marks WA, Morris MP, Bodensteiner JB, et al. Gastritis with valproate therapy. Arch Neurol 1988;45:903-5
  • Bryant AE, Dreifuss FE. Valproic acid hepatic fatalities, III: US experience since 1986. Neurology 1996;46:465-9
  • Dreifuss FE, Santilli RN, Langer DH, et al. Valproic acid hepatic fatalities. A retrospective review. Neurology 1987;37:379-85
  • Duarte J, Macias S, Coria F, et al. Valproate induced coma: case report and review. Ann Pharmacother 1993;27:582-3
  • Koenig SA, Buesing D, Longin E, et al. Valproic acid-induced hepatopathy: nine new fatalities in Germany from 1994 to 2003. Epilepsia 2006;47:2027-31
  • Nurge ME, Anderson CR, Bates EB. Metabolic and nutritional implications of valproic acid. Nutr Res 1991;11:949-60
  • Cotarlu D, Zaldman L. Valproic acid and the liver. Clin Chem 1988;34:890-7
  • Jimenez-Rodriguezvila M, Caro-Paton A, Duenas-Laita A, et al. Histological, ultrastructural and mitochondrial oxidative phosphorylation studies in liver of rats chronically treated with oral valproic acid. J Hepatol 1985;1:453-65
  • Rogiers V, Vandenberghe Y, Vercruysse A. Inhibition of gluconeogenesis by sodium valproate and its metabolites in isolated rat hepatocytes. Xenobiotica 1985;15:759-66
  • Hjelm M, Oberholzer V, Seakins J, Thomas S, Kay JDS. Valproate inhibition of urea synthesis. Lancet 1987;i:923
  • Zafrani ES, Bethelot P. Sodium valproate in the induction of unusual hepatotoxicity. Hepatology 1982;2:648-9
  • Murakami K, Sugimoto T, Woo M, et al. Effect of L-carnitine supplementation on acute valproate intoxication. Epilepsia 1996;37:687-9
  • Thurston JH, Hauhart RE. Reversal of the adverse chronic effects of the unsaturated derivative of valproic acid – 2-n-propyl-4-pentenoic acid – on ketogenesis and liver coenzyme A metabolism by a single injection of pantothenate, carnitine, and acetylcysteine in developing mice. Pediatr Res 1993;33:72-6
  • Kim AJ, Shi Y, Austin RC, Werstuck GH. Valproate protects cells from ER stress-induced lipid accumulation and apoptosis by inhibiting glycogen synthase kinase-3. J Cell Sci 2005;118:89-99
  • Siemes H, Nau H, Schultze K, et al. Valproate metabolites in various clinical conditions of probable VPA-associated hepatotoxicity. Epilepsia 1993;34:332-46
  • Lheureux PE, Penaloza A, Zahir S, Gris M. Science review: carnitine in the treatment of valproic acid-induced toxicity – what is the evidence? Crit Care 2005;9:431-40
  • Cuturic M, Abramson RK. Acute hyperammonemic coma with chronic valproic acid therapy. Ann Pharmacother 2005;39:2119-22
  • Rath A, Naryanan TJ, Chowdhary GV, Murthy JM. Valproate-induced hyperammonemic encephalopathy with normal liver function. Neurol India 2005;53:226-8
  • Gerstner T, Buesing D, Longin E, et al. Valproic acid induced encephalopathy – 19 new cases in Germany from 1994 to 2003 – a side effect associated to VPA-therapy not only in young children. Seizure 2006;15:443-8
  • Longin E, Teich M, Koelfen W, Koenig SA. Topiramate enhances the risk of valproate associated side effects in three children. Epilepsia 2002;43:451-4
  • Kwan P, Brodie MJ. Neuropsychological effects of epilepsy and antiepileptic drugs. Lancet 2001;357:216-22
  • Ricard C, Martin K, Tournier M, et al. A case of Parkinsonian syndrome, cognitive impairment and hyperammonemia induced by divalproate sodium prescribed for bipolar disorder. Encephale 2005;31:98-101
  • Verrotti A, Trotta D, Morgese G, Chiarelli F. Valproate-induced hyperammonemic encephalopathy. Metab Brain Dis 2002;17:367-73
  • Alonso E, Girbes J, Garcia-Espana A, Rubio V. Changes in urea cycle-related metabolites in the mouse after combined administration of valproic acid and an amino acid load. Arch Biochem Biophys 1989;272:267-73
  • Laub MC. Hyperammonemia in valproate therapy in children and adolescents. Nervenarzt 1986;57:314-8
  • Nitu-Whalley IC, Lee CA. Acquired von Willebrand syndrome – report of 10 cases and review of the literature. Haemophilia 1999;5:318-26
  • Pohlmann-Eden B, Peters CN, Wennberg R, Dempfle CE. Valproate induces reversible factor XIII deficiency with risk of perioperative bleeding. Acta Neurol Scand 2003;108:142-5
  • Teich M, Longin E, Dempfle CE, Koenig S. Factor XIII deficiency with valproate treatment. Epilepsia 2004;45:187-9
  • Bjerkedal T, Czeizel A, Goujard J, et al. Valproic acid and spina bifida. Lancet 1982;2:1096
  • Frey L, Hauser WA. Epidemiology of neural tube defects. Epilepsia 2003;44:4-13
  • Tabatabaei AR, Abbott FS. Assessing the mechanism of metabolism dependant valproic acid-induced in vitro cytotoxicity. Chem Res Toxicol 1999;12:323-30
  • Verrotti A, Tana M, Pelliccia P, et al. Recent advances on neural tube defects with special reference to valproic acid. Endocr Metab Immune Disord Drug Targets 2006;6:25-31
  • Keränen T, Sivenius J. Side effects of carbamazepine, valproate and clonazepam during long-term treatment of epilepsy. Acta Neurol Scand 1983;97(Suppl):69-80
  • Deckers CL, Hekster YA, Keyser A, et al. Adverse effects in epilepsy therapy. Wait and see or go for it? Acta Neurol Scand 1997;95:248-52

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.